FDA Inspection 1315568 — Axogen Corporation
The FDA completed an inspection of Axogen Corporation on April 9, 2026 in Dayton, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 9, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Dayton, OH (United States)